A Phase 1/2 Study of Gilteritinib and Momelotinib in Adults With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia (SOHO 2026) - Sep 1, 2026 - Abstract #AML-1687; Location: LEVEL 3, HALL B3; "Gilteritinib+momelotinib (≤600 mg daily) was safe and demonstrated encouraging preliminary activity in heavily pretreated R/R FLT3-mutated AML, including cases with prior gilteritinib and quizartinib exposure. ACVR1: activin A receptor type 1, AML: acute myeloid leukemia, CRc: composite complete remission, CRi: complete remission with incomplete hematologic recovery, FLT3: FMS-like tyrosine kinase 3, ITD: internal tandem duplication, JAK: Janus kinase, MLFS: morphologic leukemia-free state, PB: peripheral blood, R/R: relapsed/refractory, SMAD: small mothers against decapentaplegic, STAT: signal transducer and activator of transcription, TKD: tyrosine kinase domain, VAF: variant allele frequency."
Clinical • P1/2 data • Acute Myelogenous Leukemia • Oncology • ACVR1 • FLT3 • JAK1 • JAK2 • SMAD4
|
|
Leticia Campoverde MD; Maria Hachem MD; Farhad Ravandi MD; Guillermo Garcia-Manero MD; Gautam Borthakur MD; Naval Daver MD; Guillermo Montalban Bravo MD; Ian Bouligny MD; Musa Yilmaz MD; Danielle Hammond MD; Steven Kornblau MD; Mahesh Swaminathan MD; Courtney DiNardo MD,MSCE; Wei Qiao; Regina Abramova; Brianna Kammerer; Hussein Abbas MD PhD; Nicholas Short MD
|